Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Colorado Health Reporter.
Press releases published on May 13, 2025
MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers
GlobeNewswire
·
May 13, 2025
YAVNE, Israel, May 13, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the publication of a peer-reviewed post hoc analysis in Wounds. The analysis is …
First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study
GlobeNewswire
·
May 13, 2025
- ATTRibute-CM, BridgeBio’s Phase 3 clinical trial of acoramidis in patients with ATTR-CM, achieved statistical significance in reducing the risk of ACM or first CVH versus placebo in ATTRv-CM patients (59.1% risk reduction), establishing the mechanistic …
Knight présentera à la conférence sur la santé internationale de 2025 de RBC Marchés des Capitaux à New York
GlobeNewswire
·
May 13, 2025
MONTRÉAL, 13 mai 2025 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight »), société pharmaceutique spécialisée panaméricaine (ex-ÉU), a annoncé aujourd'hui que Samira Sakhia, présidente et chef de la direction, participera à une …
XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements
GlobeNewswire
·
May 13, 2025
Pipeline advancements: The Marketing Authorization Application (MAA) for Day One Biopharmaceuticals and Ipsen’s tovorafenib was accepted for review by the European Marketing Authority (EMA) and Takeda initiated its Phase 3 trial exploring mezagitamab for …
Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates
GlobeNewswire
·
May 13, 2025
BURLINGTON, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates …
Prime Biome Reviews (Consumer Report 2025): The Gut Health and Skin Supplement That’s Getting Noticed
GlobeNewswire
·
May 13, 2025
SAN JOSE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- I’ll be honest—I've tried more probiotics than I can count. From popular capsules at local stores to trendy gummies delivered from across the country, none of them lived up to the hype. Some offered short- …
Plantsulin Reviews Consumer Reports 2025: Does It Really Work? The Truth Behind the Hype Exposed!
GlobeNewswire
·
May 13, 2025
SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- In this Article, You’ll Learn: Why standard blood sugar advice doesn’t always work in real life — and what might actually make a difference How Plantsulin delivers plant-powered support for balanced glucose …
Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update
GlobeNewswire
·
May 13, 2025
Company Seeking Conditional Approval from European Medicines Agency (EMA) for Iopofosine I 131 in Waldenstrom Macroglobulinemia based upon CLOVER WaM Phase 2 Study Data CLOVER WaM Major Response Rate for BTKi-Treated Patients 59.0% Company to hold webcast …
Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025
GlobeNewswire
·
May 13, 2025
PRINCETON, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody- …
Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
GlobeNewswire
·
May 13, 2025
WALTHAM, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that management will participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 20, 2025, at 11:00 a.m. ET in …
Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting
GlobeNewswire
·
May 13, 2025
In vivo CRISPR Editing Results in Functional Upregulation of a Liver Target Protein and Meaningful Reduction of Disease-Associated Biomarker in Mice CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene …
atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder
GlobeNewswire
·
May 13, 2025
- In a Phase 1 study, EMP-01 (oral R-MDMA) demonstrated a unique, dose-dependent subjective effect profile that was generally found to be more similar to classical psychedelics than to racemic MDMA - The exploratory, randomized, double-blind, placebo- …
Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 13, 2025
Enrollment of 1L NSCLC patients in China trial of AXN-2510/IMM2510 in combination with chemotherapy is ongoing with initial clinical data by ImmuneOnco expected in 2H 2025 Initiation of U.S. clinical study of AXN-2510/IMM2510 in combination with …
Orchard Therapeutics Announces New England Journal of Medicine Publication of Long-term Clinical Outcomes from its HSC Gene Therapy for MLD and Multiple Presentations at ASGCT 2025
GlobeNewswire
·
May 13, 2025
LENMELDY™ is the first and only disease-modifying intravenous infusion proven to extend life expectancy in pre-symptomatic late infantile (PSLI) patients and mitigate the cognitive and/or physical impact of early-onset MLD Six accepted abstracts at ASGCT …
Immatics Announces First Quarter 2025 Financial Results and Business Update
GlobeNewswire
·
May 13, 2025
IMA203 PRAME Cell Therapy: Randomized-controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing and expected to complete enrollment in 2026 IMA203 PRAME Cell Therapy: Phase 1b clinical trial ongoing with updated data in metastatic …
EyePoint Announces Participation at Upcoming Investor Conferences
GlobeNewswire
·
May 13, 2025
WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced …
Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
GlobeNewswire
·
May 13, 2025
FREDERICK, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate …
Legend Biotech Reports First Quarter 2025 Results and Recent Highlights
GlobeNewswire
·
May 13, 2025
CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $369 million Over 6,000 patients treated to date Initiated CARVYKTI® clinical production at the Tech Lane facility Received positive CHMP opinion to add statistically …
Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ISPOR 2025
GlobeNewswire
·
May 13, 2025
REDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will present data on the burden …
Altimmune Announces First Quarter 2025 Financial Results and Business Update
GlobeNewswire
·
May 13, 2025
Top-line data from IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) expected in Q2 2025 Phase 2 trials in Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD), expected to initiate in Q2 and Q3 2025, …